Breaking News: MESO – Market Insights, Analysis & Latest Updates

MESO

Mesoblast stock soars on FDA approval of Ryoncil

Mesoblast's Ryoncil, the first MSC therapy approved by the FDA, shows 70% efficacy in treating SR-aGvHD in children, marking a major milestone in medical treatment.

investing.com • 19/12/2024 - 12:26 PM

MESO

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

The FDA approved Mesoblast's Ryoncil for treating pediatric graft-versus-host disease (GVHD), the first cell therapy for patients unresponsive to standard steroid treatment.

investing.com • 18/12/2024 - 21:57 PM

MESO

Earnings call: Mesoblast eyes FDA approvals, advances RYONCIL launch

Mesoblast reports progress on FDA reviews and strategic plans for RYONCIL and other products, with a cash balance of $63.3 million and preparations for commercial launches.

investing.com • 29/08/2024 - 09:47 AM

Greed and Fear Index

Note: The data is for reference only.

Greed

Mesoblast stock soars on FDA approval of Ryoncil

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Earnings call: Mesoblast eyes FDA approvals, advances RYONCIL launch

Currency